Market Analysis on 5-Hydroxytryptamine Receptor 6 -Pipeline Review, H1 2016

5-Hydroxytryptamine Receptor 6 (5-HT-6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H1 2016 is a new market research publication announced by Reportstack. This report provides in depth analysis on 5-Hydroxytryptamine Receptor 6 (5-HT-6 or Serotonin Receptor 6 or HTR6) targeted pipeline therapeutics.

The report provides comprehensive information on the 5-Hydroxytryptamine Receptor 6 (5-HT-6 or Serotonin Receptor 6 or HTR6), targeted therapeutics, complete with analysis by indications, stage of development, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in 5-Hydroxytryptamine Receptor 6 (5-HT-6 or Serotonin Receptor 6 or HTR6) targeted therapeutics development and features dormant and discontinued projects.

To access full report with TOC, please visit ​5-Hydroxytryptamine Receptor 6 (5-HT-6 or Serotonin Receptor 6 or HTR6) - Pipeline Review, H1 2016.

The report is built using data and information sourced from proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage.

Scope

- The report provides a snapshot of the global therapeutic landscape for 5-Hydroxytryptamine Receptor 6 (5-HT-6 or Serotonin Receptor 6 or HTR6)
- The report reviews 5-Hydroxytryptamine Receptor 6 (5-HT-6 or Serotonin Receptor 6 or HTR6) targeted therapeutics under development by companies and universities/research institutes based on information derived from company and industry-specific sources 
- The report reviews key players involved in 5-Hydroxytryptamine Receptor 6 (5-HT-6 or Serotonin Receptor 6 or HTR6) targeted therapeutics and enlists all their major and minor projects 
- The report assesses 5-Hydroxytryptamine Receptor 6 (5-HT-6 or Serotonin Receptor 6 or HTR6) targeted therapeutics based on mechanism of action (MoA), route of administration (RoA) and molecule type 

Reasons to buy

- Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies
- Identify and understand the targeted therapy areas and indications for 5-Hydroxytryptamine Receptor 6 (5-HT-6 or Serotonin Receptor 6 or HTR6)
- Devise corrective measures for pipeline projects by understanding 5-Hydroxytryptamine Receptor 6 (5-HT-6 or Serotonin Receptor 6 or HTR6) development landscape 
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope


Companies Mentioned

Adamed Sp. z o.o. Avineuro Pharmaceuticals, Inc. Axovant Sciences Ltd. Biotie Therapies Corp. Galenea Corp. H. Lundbeck A/S Reviva Pharmaceuticals Inc. Suven Life Sciences Ltd. Teva Pharmaceutical Industries Ltd.

Contact:

Debora White

Manager - Marketing

debora@reportstack.com

Ph: +1-888-789-6604

Reportstack Market Research

###